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Abstract 
 It is generally recognized that the major obstacle to efficient gene delivery is cellular 
internalization and endosomal escape of the DNA. Recently, we have developed a modular 
strategy for the preparation of well-defined polycationic amphiphilic cyclodextrins (paCDs) 
capable of complexing and compacting DNA into homogeneous nanoparticles (<70 nm). 
Since paCDs resemble both cationic polymers and cationic lipids, it is conceivable that the 
corresponding pDNA-paCD nanoparticles (CDplexes) might use the cell uptake and 
endosomal escape mechanisms described for both lipoplexes and polyplexes. To verify this 
hypothesis, we have now investigated the uptake and transfection efficiencies of CDplexes in 
the presence of several inhibitors of endocytosis, namely chlorpromazine, genistein, dynasore 
and methylated β-cyclodextrin (MbCD). Our data show that CDplexes obtained from paCD 1, 
which ranks among the most efficient paCD gene vectors reported up to date, are internalized 
by both clathrin-dependent (CDE) and clathrin-independent endocytosis (CIE), both processes 
being cholesterol- and dynamin-dependent. We observed that the largest fraction of gene 
complexes is taken up via CDE, but this fraction is less relevant for transfection. The smaller 
fraction that is internalized via the CIE pathway is predominantly responsible for successful 
transfection. 
 
Introduction 
 
The successful delivery of therapeutic genes into cells and their availability at the 
intracellular site of action are crucial requirements for successful gene therapy. During the last 
decade, under the advent of nanotechnology, a broad diversity of creative materials featuring 
promising properties for nonviral gene delivery applications has emerged, (1). Cationic 
polymers and lipids, or their combinations, have shown the ability to bind nucleic acids 
through electrostatic interactions and condense them into complexes that can be readily 
internalized by cells (2-3). The gene delivering capabilities of many of these systems have 
been thoroughly investigated. Yet, drawing firm conclusions that might serve to provide 
feedback for the design of improved delivery entities is a delicate issue as a consequence of 
the essentially polydisperse nature of such structures (4). 
The control of the architecture of multifunctional macromolecules is a major 
determinant in the rational design of successful nonviral gene delivery systems. Novel 
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strategies have been implemented to build up well defined constructs featuring self-
assembling capabilities in the presence of nucleic acids. In this context, the unique 
characteristics of dendrimers and other highly ordered clusters, such as uniformity, 
monodispersity and multivalency, have attracted increasing attention (5-8). Homogeneous 
external functionalization of these platforms becomes, however, exponentially more 
complicated as the dendrimer generation increases (9-10). The use of preorganized 
macrocyclic scaffolds, such as calixarenes, to achieve a precise alignment of functional 
elements represents an interesting alternative (11-14). The commercially available 
cyclomaltooligosaccharides (cyclodextrins; CDs) appear particularly attractive on those 
grounds (15-16). CDs combine biocompatibility, availability, and a tubular symmetric 
framework with well differentiated faces that can be selectively modified in order to attain an 
exquisite control of the presentation and orientation of the assembled elements (17-19). 
Chemically modified CDs have been already incorporated into polycationic polymers that can 
effectively complex and deliver plasmid DNA (pDNA) (20-21). More recently, monodisperse 
polycationic CD conjugates with promising pDNA delivery capabilities were prepared by 
homogeneous functionalization of the CD primary rim (22-24). Aiming at merging the virtues 
of both cationic polymers and cationic lipids in a flexible, well defined framework, we have 
reported a modular synthetic strategy for the preparation of polycationic amphiphilic CDs 
(paCDs) that allows the installation of different building blocks onto either face of the 
truncated-cone structure in a sequential and controlled way, offering a unique opportunity for 
structure-activity relationship (SAR) studies (25-27) (Figure 1). The pDNA complexing 
capabilities and in vitro transfection efficiencies of the corresponding pDNA-paCDs 
complexes (CDplexes) were found to be dependent on the CD decoration pattern. Notably, 
transfection efficiencies surpassing that of commercial polyethyleneimine (PEI) polymers-
based polyplexes for BNL-CL2 and COS-7 cell lines were observed for some paCD 
representatives, such as 1 (28) (Figure 2). Since paCDs resemble both cationic polymers and 
cationic lipids, it is conceivable that the resulting pDNA-paCD nanoparticles (CDplexes) 
might be taken up by the cells and later released from the endosomes by mechanisms earlier 
described for both lipo- and polyplexes.  
In eukaryotic cells the following mechanisms of endocytosis can be distinguished:  
phagocytosis, macropinocytosis (MP), clathrin dependent endocytosis (CDE) and clathrin 
independent endocytosis (CIE) (29). Phagocytosis is typically restricted to specialized cells 
such as macrophages, whereas macropinocytosis is a constitutive bulk internalization process 
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typically characterized by the formation of membrane protrusions and engulfing large 
volumes (30). CDE and CIE are the most relevant mechanisms operating in the internalization 
of pDNA-nonviral gene delivery system complexes. The first route is characterized by the 
formation of clathrin coated pits (31). CIE includes several pathways which share a 
cholesterol dependency (32), among which caveolin mediated endocytosis Cav-ME is 
probably the most thoroughly characterized. In this case the membrane of the formed vesicles, 
which are called cavicles, typically contains caveolin-1 (33,34). Selective inhibition of the 
different internalization pathways has been shown to be a powerful tool to investigate uptake 
mechanisms of nanoparticles and infer the relevance of the blocked pathway in the 
internalization mechanism (32,35-43). Previous studies have shown that lipoplexes enter the 
cells predominantly via CDE (44). Polyplexes, however, are internalized less uniformly. Their 
uptake seems to occur via MP and CDE as well as CIE (44). Nonetheless, it has been 
observed for PEI complexes that it is predominantly the fraction that is taken up via CIE that 
leads to gene expression (45-47). 
The purpose of this work was to get insight on the uptake mechanisms of pDNA-paCD 
nanoparticles and study whether the different internalization pathways might influence the 
intracellular fate of the CDplexes and their transfection efficiency. The dendritic 
tetradecacationic paCD 1, for which a gram-scale synthetic procedure has been optimized, 
was selected for this study since it was previously shown to form small (< 70 nm) CDplexes 
in which pDNA was fully protected from degradation, with transfection efficiencies up to one 
order of magnitude higher as compared to branched PEI (25 KDa) in BNL-CL2 and COS-7 
cells both in serum free and serum-containing (10%) media (28).  A set of selective endocytic 
pathway inhibitors, including chlorpromazine, genistein, dynasore and methylated β-
cyclodextrin (MbCD), have been used in the present study. In addition, a fluorescently labeled 
(lissamine-rhodamine) derivative of paCD 1 has been synthesized to study uptake and 
intracellular trafficking of the CDplexes by confocal laser scanning microscopy.  
Exper imental Section 
 
General Methods 
Reagents and solvents were purchased from commercial sources and used without 
further purification, except for dichloromethane, which was distilled over CaH2 under N2 
stream. Products 2 (48), 6 (15) and 7 (15) were prepared according to literature procedures. 
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Optical rotations were measured at 20 ºC in 1-dm tubes. 1H (and 13C) NMR spectra were 
recorded at 500 (125.7) or 300 (75.5) MHz. 2D COSY and HMQC experiments were used to 
assist NMR assignments. Thin-layer chromatography (TLC) was carried out on silica-coated 
aluminum sheets, with visualization by UV light and by charring with 10% H2SO4 or 0.1% 
ethanolic ninhydrin. Column chromatography was carried out on silica gel (230-400 mesh). 
Electrospray mass spectra were obtained from samples dissolved in MeOH, MeCN, H2O or 
their mixtures at low µM concentration. Ampicillin, chlorpromazine, methyl β-cyclodextrin 
(MbCD), genistein and dynasore were purchased from Sigma Aldrich (Bornem, Belgium). 
Serumfree medium OptiMEM is purchased from Invitrogen (Merelbeke, Belgium). 
Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy]cyclomaltoheptaose 
(3). To a suspension of heptakis(6-bromo-6-deoxy)cyclomaltoheptaose (48) (2, 2.52 g, 1.59 
mmol) and cesium carbonate (5.13 g, 15.6 mmol) in dry DMF (30 mL), tert-butyl N-(2-
mercaptoethyl)carbamate  (15.9 mmol, 1.4 eq) was added. The suspension was heated, under 
Ar atmosphere, at 70 ºC for 48 h. The reaction mixture was cooled to room temperature, 
poured into ice-water, and stirred overnight. The resulting solid was filtered, washed with a 
large volume of water and finally washed with a small amount of cold Et2O. The residue was 
purified by column chromatography (40:10:1 → 30:10:1 CH 2Cl2-MeOH-H2O) to give 3 (3.04 
g, 85%) having physicochemical properties identical to those previously reported (28). 
Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy-2,3-di-O-
hexanoyl]cyclomaltoheptaose (4): To a solution of 3 (2.0 g, 0.89 mmol) in dry pyridine (10 
mL) under Ar, DMAP (4.56 g, 37.3 mmol, 3 eq) and hexanoic anhydride (12 mL, 49.8 mmol, 
4.0 eq) were added. The mixture was heated at 70 ºC for 4-5 h. Then, MeOH (10 mL) was 
added and the mixture was further stirred at 70 ºC for 3 h. The solvents were evaporated under 
reduced pressure, ice-water (50 mL) was added and extracted with CH2Cl2 (4 × 50 mL). The 
organic phase was washed with diluted sulfuric acid (2 × 50 mL) and cold aqueous saturated 
NaHCO3 (4 × 50 mL), dried (Na2SO4), filtered, concentrated and purified by column 
chromatography (1:3 EtOAc-petroleum ether) to give 4 (2.44 g, 76%) having 
physicochemical properties identical to those previously reported (28). 
Heptakis[6-(2-aminoethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose 
Heptahydrochloride (5): Treatment of carbamate 4 (1.42 g, 0.4 mmol) with 1:2 TFA-CH2Cl2 
(20 mL) at RT for 3 h, followed by evaporation of the solvents and freeze-drying from a 
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diluted HCl solution, gave pure 5 (1.20 g, 99%) as a white foam having physicochemical 
properties identical to those previously reported (28). 
2-[Bis[2-(tert-butoxycarbonylamino)ethyl]amine]ethyl Isothiocyanate (8). To a 
solution of 2-azidoethyl-bis[2-(tert-butoxycarbonylamino)ethyl]amine (15) (7, 0.72 g, 1.89 
mmol) in dry dioxane (15 mL), triphenylphosphine (0.55 g, 1.1 eq, 2.1 mmol) and carbon 
disulfide (1.14 mL, 10 eq, 18.9 mmol) were added. The reaction mixture was stirred under N2 
atmosphere for 16 h. Then the solvent was removed under reduced pressure and the residue 
was purified by column chromatography using 1:2 EtOAc-petroleum ether as eluent to give 8 
(0.63 g, 86 %) having physicochemical properties identical to those previously reported (28). 
Heptakis[6-deoxy-6-(2-(N’-(2-(N,N-di-(2-(N-tert-
butoxycarbonylamino)ethyl)amino)ethyl)-thioureido)ethylthio)-2,3-di-O-
hexanoyl]cyclomaltoheptaose (9). To a solution of 5 (0.48 g, 0.15 mmol) and Et3N (0.29 
mL, 2.12 mmol, 2.0 eq) in CH2Cl2 (5 mL), a solution of 8 (0.49 g, 1.26 mmol, 1.2 eq) in 
CH2Cl2 (5 mL) was added and the reaction mixture was stirred at RT for 3 h. The solvent was 
evaporated under reduced pressure and the residue was purified by column chromatography 
(50:1 → 20:1 CH 2Cl2-MeOH) to give 9 (0.72 g, 85%) having physicochemical properties 
identical to those previously reported (28). 
Heptakis[6-deoxy-6-(2-(N’-(2-(N,N-di-(2-
aminoethyl)amino)ethyl)thioureido)ethylthio)-2,3-di-O-hexanoyl]cyclomaltoheptaose (1). 
Treatment of carbamate 9 (0.6 g, 0.11 mmol) with 1:2 TFA-CH2Cl2 at RT for 3 h, followed by 
evaporation  of the solvent and freeze-drying from diluted HCl solution, gave 1 (0.50 g) in 
quantitative yield. Its identity and purity was confirmed by ESI-MS, comparison of the 
corresponding 1H and 13C NMR spectra with those of an authentic sample (28) and 
combustion analysis. 
Lissamine-Rhodamine Labeled paCD 10. To a solution of paCD 1 (83 mg, 17 µmol) 
and Et3N (50 µL, 0.35 mmol) in freshly distilled CH2Cl2 (10 mL) under N2, lissamine-
rhodamine sulfonyl chloride (LRSC, 10 mg, 17 µmol) was added. The reaction was stirred at 
RT for 2 days in the dark. The solvents were then removed under vacuum and the residue was 
purified by size exclusion chromatography (Sephadex LH-20, MeOH). Lisamine-Rhodamine 
labeled paCD 10 was obtained as a dark red foam after liophilization from diluted HCl (73 
mg, 79%). The corresponding 1H NMR spectrum, recorded in MeOD at 313 K, featured the 
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characteristic aromatic signals for lissamine-rhodamine (LS) at δ 8.75, 8.24, 7.62 and 7.26-
6.97 ppm, with intensities fitting the expected 1:1 LS-paCD average ratio. ESI-MS: m/z 
1196.5 [M-Rho + 4 H]4+, 1061.5 [M + 4 H]4+, 957.3 [M-Rho + 5 H]5+, 848.8 [M + 5 H]5+. 
Plasmid Preparation and Labeling.  
For transfection, the luciferase encoding plasmid pGL4.13 (Promega, Leiden, The 
Netherlands) was used. The plasmid was transformed into the competent E. coli DH10b strain 
(Promega, Leiden, The Netherlands) according to the manufacturer’s instructions. The 
transformed bacteria were then selected for ampicillin resistance and grown till an optical 
density of 1.5. The plasmid was purified with the PureLink™ HiPure Plasmid Gigaprep Kit 
(Invitrogen, Merelbeke, Belgium). The plasmid was re-suspended to a concentration of 1 µg 
µL-1 in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4). For uptake studies, the plasmid was 
labeled with the nucleic acid stain YOYO®-1 iodide (λex = 491, λem = 509, Molecular Probes, 
Merelbeke, Belgium). For the labeling, 100 µg of plasmid was added to 15 nmol of YOYO-1 
in 20 mM HEPES buffer for 1 h at RT, which should result in a labeling density of 1 YOYO-
dye per 10 bp. The YOYO-1-DNA complexes were finally purified by an ethanol 
precipitation and re-suspended to 1 µg µL-1 in TE buffer. 
Preparation of CDplexes.  
To prepare complexes, plasmid DNA was mixed with polycationic amphiphilic 
cyclodextrins. The paCD derivative was dissolved in DMSO and diluted in water to a final 
stock solution of 20 mg·mL-1 (4.2 mM) (1:2 DMSO-water). pDNA was diluted with 
OptiMEM to a concentration of 0.04 µg µL-1 (equal to 124 µM of phosphate) and mixed with 
paCD derivate to yield the desired N/P ratio. The preparation was vortexed for 12 minutes 
before diluting it 10 times in OptiMEM. This solution was used for uptake or transfection 
experiments. 
Cell Culture 
Vero (African green monkey kidney epithelial cell line; ATCC number CCL-81) were 
cultured in Dulbecco’s modified Eagles’ medium (DMEM; Invitrogen, Merelbeke, Belgium) 
supplemented with 10 % fetal bovine serum (Perbio, Erembodegem, Belgium), 2 mM L-
glutamine and 2 % penicillin/streptomycin (Invitrogen, Merelbeke Belgium) and grown at 37 
°C in a humidified atmosphere containing 5 % CO2. 
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Transfection experiments 
Cells were seeded into 12-well plates (100.000 cells per well) and allowed to attach 
overnight. Subsequently, the culture medium was removed and CDplexes were added to the 
well (2 µg of DNA, N/P 10). The complexes were removed after 4 h. Luciferase activity, as 
well as the total cellular protein concentration, was measured after 48 h. To determine the 
luciferase activity, the cells were washed with PBS and lysed with 200 µL of cell culture lysis 
buffer (Promega, Leiden, The Netherlands) (30 min, RT). Samples were centrifuged (4 ºC, 
14000 rpm, 5 min). Subsequently, luciferase activity was determined in the supernatants with 
the Promega luciferase assay kit (Promega, Leiden, The Netherlands) according to the 
manufacturer's instructions. Briefly, 100 µL of substrate solution were added to 40 µL sample 
in a white 96-microtiter plate and after a 2 s delay, the luminescence was measured during 10 
s with the GloMax™ 96 luminometer (Promega, Leiden, The Netherlands). The protein 
concentration was determined with the Biorad Bradford Protein assay (Biorad, Eke, Belgium). 
The Biorad reagent (50 µL) was mixed with cell lysate (2 µL) and water (198 µL) in a 
transparent 96-microtiter plate and the absorbance was measured on a Wallac Victor2 
absorbance plate reader (Perkin Elmer-Cetus Life Sciences) at 590 nm. The luciferase 
activity, expressed as relative light units (RLU) per µg of protein, was used as a measure for 
the efficiency of transfection with the CDplexes. Mean values were obtained from at least two 
separate experiments carried out in triplicate. 
Cell Viability Assay 
Cell viability was assessed with the CellTiterGlo Proliferation Assay (Promega, 
Leiden, The Netherlands) according to the manufacturer's instructions. Briefly, 10.000 Vero 
cells were seeded in a white 96-well microtiter plate with transparent bottom (Greiner Bio-
One, Wemmel, Belgium). The cells were treated with 100 µL of inhibitors and/or complexes 
for the indicated times. Subsequently, CellTiterGlo reagent was added and incubated with the 
cells for 5 min till complete lysis. Cell debris was spun down and luminescence was measured 
in the supernatants on a GloMax™ 96 luminometer with 1 s integration time. Each experiment 
was performed in quadruplicate.  
CDplexes Uptake Studies 
Vero cells were seeded into 6-well plates (300.000 cells per well) and allowed to 
attach overnight. The cells were then incubated with the CDplexes, prepared with YOYO-1 
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labeled pDNA, in OptiMEM. The fluorescence of the non-internalized complexes, attached to 
the plasma membrane was quenched by a 5-minute-washing with 0.2% trypan blue (Sigma, 
Bornem, Belgium) in PBS solution. After washing with PBS, the cells were detached with 
trypsin, centrifuged and re-suspended in ice cold flow buffer. The samples were analyzed with  
a 5-color FC500 flow cytometer (Beckman Coulter, Nyon, Switzerland) equipped with an 
argon laser (λex = 488 nm). CXP software (Beckman Coulter, Nyon, Switzerland) was used 
for the analysis. The internalization of CDplexes was calculated as the mean fluorescence 
value (average of three independent experiments). The 0% uptake was determined from cells 
incubated at 4 °C. The 100% uptake was determined from cells that had been incubated with 
the complexes without being exposed to any inhibitor.  
Inhibitor Studies 
Prior to incubation with CDplexes, Vero cells were pre-incubated with 
chlorpromazine, MbCD, genistein or dynasore prepared in OptiMEM (1 h, 37 °C). 
Subsequently this medium was removed and substitute with OptiMEM containing fresh 
inhibitor and complexes. The following stock solutions of inhibitors were used: freshly 
prepared 10 mg mL-1 chlorpromazine in water, freshly prepared 5 mM (6.6 mg mL-1) MbCD 
in water, 50 mM genistein in DMSO (stored in the freezer), and 1 µg µL-1 dynasore in DMSO 
(stored in the freezer). 
Live Cell Imaging of F luorescently Labeled CDplexes 
Vero cells were seeded at a concentration of 400.000 cells per well on sterile MatTek 
coverslips (1.5)-bottom dishes (MatTek Corporation, MA, USA). The cells were incubated 
with 2 mL of CDplexes (N/P 10, 12 µg DNA). The fluorescent CDplexes were visualized 
with a Nikon C1 confocal laser scanning microscope (CLSM) (Nikon Benelux, Brussels, 
Belgium) equipped with a Plan Apo VC 60x 1.4 NA oil immersion objective lens. Lissamine-
rhodamine labeled compound (10) was excited with the solid state 561 nm laser line and the 
emitted light was collected using a 580-630 nm band pass filter. Cells were kept in a stage top 
incubator with controlled temperature, humidity and CO2 pressure (Tokai Hit, Shizuoka, 
Japan). Representative 2D confocal images were acquired approximately through the central 
plane of the cell. 
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Results and Discussion 
 
Synthesis  
The paCD representative selected for this study (1) incorporates a cluster of fourteen 
primary amino groups that can act cooperatively with a belt of thiourea segments in the 
reversible complexation of the polyphosphate skeleton of plasmids through concerted 
electrostatic and hydrogen bonding interactions. It contains, additionally, a rim of tertiary 
amino groups intended to mimic the pH-regulating effect ascribed to tertiary amines in PEI 
polymers (49). Its synthesis had previously been accomplished, though only in the 10 mg 
scale (28). For the purpose of this work, and in view of further studies, we have scaled up the 
preparation of 1 to the gram scale through the reaction sequence depicted in Scheme 1. The 
key step is the coupling reaction of the isothiocyanate-functionalized Boc-protected 
polyamine dendron 8 with the βCD heptaamine scaffold 5, in which the lipophilic hexanoyl 
tails have already been installed. The preparation of the heptacationic βCD precursor was 
effected in four steps from commercial βCD by a reaction sequence involving primary face-
selective bromination with N-bromosuccinimide (→2) (48), nucleophilic displacement of the 
halogen groups by N-Boc-protected cysteamine (→3), homogeneous acylation of the 
secondary hydroxyls with hexanoic anhydride and N,N-dimethylaminopyridine (DMAP) in 
pyridine (→4), and final acid-promoted hydrolysis of the carbamate groups. This synthetic 
route proved to be very convenient, furnishing compound 5 with analytical purity in a 
consistent 60% overall yield in gram scale. 
The coupling reaction of isothiocyante 8 and heptaamine 5 proceeded to completion in 
dichloromethane in the presence of triethylamine, as monitored by TLC and ESI-MS (→9). 
After chromatographical purification, the corresponding heptathiourea adduct was isolated in 
85% yield. Trifluoroacetic acid-mediated hydrolysis of the Boc protecting groups furnished 
the target paCD 1 in quantitative yield, which was characterized and stored as the 
corresponding tetradecahydrochloride salt. 
In order to monitor real time cell uptake of pDNA:paCD nanoparticles by advanced 
light microscopy techniques, compound 1 was covalently labeled with lissamine-rhodamine. 
This fluorescent probe offers chemical stability and strong fluorescence intensity over a wide 
range of conditions (pH and ionic strength) and can be easily installed on amine-bearing 
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macromolecules. Thus, compound 1 was reacted with lissamine-rhodamine sulfonyl chloride 
(LRSC) in CH2Cl2 in equimolecular relative proportion, in order to obtain an average 
incorporation of one fluorescent probe per paCD molecule (Scheme 2).  The resulting 
lissamine-rhodamine labeled paCD (10) was finally purified by size-exclusion 
chromatography. Compounds 1 and 10 (and their combined formulations) featured 
comparable self assembling capabilities in the presence of plasmids. Fluorescence of 10, 
though less intense than LRSC, proved to be sufficient for imaging requirements. Maximum 
fluorescence intensity of 10 (λem 595 nm) was achieved at a concentration of 25 µM in water. 
Above this concentration, larger aggregates might be formed and self-quench fluorescence 
might occur. 
Uptake Kinetics of CDplexes 
We have previously reported that paCD 1 efficiently complexes plasmid DNA 
(pDNA) forming positively charged particles (65 nm mean hydrodynamic diameter, ζ-
potential +40 mV at N/P 10) (28). Transfection experiments with the newly prepared 1:pDNA 
(pCMV-Luc) on HeLa cells indicated that maximum transfection efficiency occurred at N/P 5 
(Figure 3). Interestingly, transfection mediated by these CDplexes was only slightly affected 
by the presence of serum, known to be a major limitation for efficient application of cationic 
carriers (Figure 3A). As expected, expression of the luciferase gene decreased over the time, 
though enzyme activity was still detectable at day 10 when the experiment was concluded 
(Figure 3B). 
The uptake kinetics of the CDplexes by Vero cells, using YOYO-1 labeled DNA, is 
presented in Figure 4. After 1 h-incubation the CDplexes were taken up by the entire 
population of the cells. The mean fluorescence, shown in the white bars, gradually increased 
till it reached a plateau after 3 h. Longer incubation times did not result in further increase of 
cell associated fluorescence. These data indicate that 2-h-incubation should be sufficient for 
efficient uptake of CDplexes by cells.  
Uptake of CDplexes was also monitored by confocal microscopy using the 
fluorescently labeled paCD 10. Snapshots at different time points are presented in Figure 5. 
Fluorescently-labeled CDplexes were internalized already 40 min after adding them to the 
cells (Figure 5A). The amount of intracellular CDplexes increased over the time, as shown in 
Figures 5B and C, and tended to accumulated in the vicinity of the nucleus. The complexes 
could be still detected intracellularly after 48 h (Figure 5D). 
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In some micrographs, large CDplex particles are visible outside the cell (Figure 5A), 
indicating that either paCD-pDNA complexes or paCD particles alone can aggregate in the 
extracellular milieu. Another interesting feature is the absence of accumulation of CDplexes 
or paCDs at the cellular membrane, ruling out the possibility of irreversible hydrophobic 
interactions between membrane lipids and the hydrocarbon tails of CDs. It is conceivable that 
in order to shield from the polar environment, hydrocarbon chains are oriented towards the 
inner core of the CDplex, which limits their interaction with plasma membrane lipids. 
Endocytosis of CDplexes in the Presence of Inhibitors 
To gain inside into the relative contribution of the different endocytotic pathways in 
CDplex-mediated transfection, four endocytosis inhibitors were applied: (i) genistein, a 
tyrosine-kinase inhibitor that causes local disruption of the actin network at the site of 
endocytosis and inhibits the recruitment of dynamin II, both known to be indispensable events 
in the caveolae-mediated uptake mechanism (50,51); (ii) dynasore, an inhibitor that blocks 
dynamin activity, disturbing the pinching off of newly formed vesicles, a process that is known 
to be essential for at least CDE (52); (iii) chlorpromazine, a cationic amphiphilic drug which 
is believed to inhibit clathrin-coated pit formation by a reversible translocation of clathrin and 
its adapter proteins from the plasma membrane to intracellular vesicles (53), and (iv) methyl 
β-cyclodextrin (MbCD), a randomly methylated cyclomaltoheptaose derivative  that inhibits 
cholesterol-dependent endocytic processes by reversibly extracting the steroid out of the 
plasma membrane (54). 
To establish an optimal protocol for the use of the inhibitors, cell viability in their 
presence was first determined. Different concentrations of each inhibitor were tested in the 
absence and in the presence of CDplexes prepared at two different N/P ratios (5 and 10). 
Cellular toxicity was assessed with the CellTiterGlo cell viability test. The results are shown 
in Figure 6. 
 Genistein alone showed limited toxicity towards Vero cells after 5 h incubation. The 
highest concentration tested (400 mM) reduced viability by less than 20% (Figure 6A). 
Incubation in the presence of genistein and CDplexes turned out to increase toxicity, 
especially at the higher N/P ratio (26% and 75% viability decrease for N/P 5 and 10, 
respectively). Dynasore (20-50 µM) displayed only moderate toxicity on Vero cells (Figure 
6B). At the highest concentration (50 µM), viability was lowered by 20% only. In 
combination with CDplexes, cell viability decreased by around 10% and 40% for N/P 5 and 
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10, respectively. Remarkably, increasing dynasore concentrations apparently protected Vero 
cells from paCDs-induced toxicity, possibly due to an efficient endocytosis blocking effect 
(see below). Vero cells were virtually insensitive to chlorpromazine up to 10 µg mL-1 for 5 h. 
Higher concentrations, on the other hand, led to 100% cell death (Figure 6C). Chlorpromazine 
at 10 mg mL-1, in combination with CDplexes (N/P 10), reduced cell viability by as much as 
70%. Treatment with MbCD caused cytotoxicity at concentrations higher than 7.5 mM (Figure 
6D), while combined incubation with MbCD (5 mM) and CDplexes (N/P 10) resulted in 50% 
cell viability.  
Inhibitor concentrations for further transfection experiments were selected based on 
the toxicity assays described above. Thus, Vero cells were preincubated for 1 h with 400 µM 
genistein, 50 µM dynasore, 10 µg mL-1 chlorpromazine or with 5 mM MbCD. Next, the cells 
were incubated for 2 h with the YOYO-1 labeled CDplexes in the presence of the 
corresponding inhibitor.  Figure 7 shows that after treatment with genistein, chlorpromazine 
and MbCD, CDplexes still were internalized by almost all the cells, albeit in lower amount. 
MbCD and chlorpromazine reduced the average cellular uptake of gene complexes by 80%, 
while genistein lowered the cellular uptake of the CDplexes only by 50%. In contrast, the 
uptake of the CDplexes was almost completely inhibited by dynasore. This would indicate 
that the uptake of CDplexes by Vero cells is strongly dependent on dynamin activity, but a 
large fraction of uptake is also dependent on the presence of cholesterol in the plasma 
membrane and the availability of clathrin at the cytoplasmic side of the plasma membrane. 
Furthermore, considering the efficient inhibition of CDplex uptake in the presence of 
chlorpromazine, known to block clathrin coated pit formation (53), we can conclude that CDE 
probably is a major route for CDplex internalization in Vero cells. However, the fact that 
genistein, known to interfere with internalization via caveolae (50), partially inhibited CDplex 
uptake does not rule out CIE routes, even if the fraction of the complexes that enter Vero cells 
via CDE seems to be larger than the fraction that enters via CIE. 
In addition to the effect of inhibitors on the uptake of complexes we measured their 
effect on transfection efficiency by assaying luciferase activity 48 h after transfection (Figure 
8). Genistein appeared to completely inhibit luciferase expression at 400 µM. Also dynasore 
inhibited transfection very efficiently at 50 µM. In the case of chlorpromazine, transfection 
efficiency was reduced by 50% at 10 µg mL-1. No luciferase activity was measured at higher 
chlorpromazine concentrations, although this is probably due to the cytotoxic combination of 
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chlorpromazine (> 10 µg mL-1) and CDplexes that resulted in almost 100% cell death (see 
above). In case of MbCD, concentrations of 5 mM or higher resulted in more than 80% 
decrease of reporter gene expression. 
Conclusions 
 Our results demonstrate that CDplex-mediated transfection is a complex process 
simultaneously involving several cellular uptake mechanisms. Chlorpromazine, an inhibitor of 
CDE, although decreasing internalization by 76%, only partially inhibited transfection. This 
indicates that the small fraction that is internalized via CIE (24%) is still able to bring about 
moderate transfection, thus reducing the relevance of CDE route for CDplex-mediated 
transfection. This result is supported by the fact that genistein, an inhibitor of CIE, although 
reducing CDplex uptake by 50% only, completely abolished luciferase expression, pointing to 
the inefficiency of clathrin-coated endosomes to deliver the pDNA functionally to its target. 
Possibly, in this case the cargo cannot escape from the endosomes and is ultimately degraded 
in lysosomal compartments. These findings are in agreement with former studies on the 
internalization of polyplexes (45-47). It must be emphasized, however, that the present 
observations and conclusions cannot be generalized or extrapolated to other types of DNA-
paCD complexes or even other cell lines. The whole process of uptake, processing and gene 
expression is strongly dependent on the carrier as well as cell type and therefore should be 
specifically studied in a case-to-case manner.   
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Figures 
Scheme 1. Convergent Synthesis of Polyaminothioureido Amphiphilic βCD (paCD) 1. 
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Scheme 2. Statistical Labeling of paCD 1 with Lissamine-Rhodamine Sulfonyl Chloride 
(LRSC). 
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Figure 1. Schematic Representation of (a) “skirt” and (b) “jelly-fish” type Polycationic 
Amphiphilic CDs (paCDs). The central light-blue platform represents the cyclodextrin core, 
the blue weaving lines account for hydrophobic chains, the orange rectangular boxes indicate 
the presence of spacer elements and the encircled + signs  stand for the positively charged 
groups. 
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Figure 2. Chemical structure of Polyaminothioureido Amphiphilic βCD 1 (colors were 
selected to match Figure 1 encoding). 
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Figure 3. In vitro transfection efficiency of pDNA:paCD nanoparticles in HeLa cells (a) in 
the presence and in the absence of serum (10%), and (b) over the time. 
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Figure 4. Uptake kinetics of YOYO-1 labeled pDNA:1 CDplexes in Vero cells.  Average cell 
fluorescence (A.U., bars) and amount of significantly fluorescent cells (%, dots) at the 
indicated time-point. The internalization was quantified with flow cytometry. 
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Figure 5. Confocal micrographs of the internalization of CDplexes in living Vero cells during 
48 h post–transfection period (A, 40 min; B, 120 min; C, 150 min; D, 2 days). 
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Figure 6. Viability of Vero cells incubated for 5 h with the inhibitors (white bars) or a 
mixture of the inhibitors and CDplexes at N/P 5 (dotted bars) and 10 (hatched bars). A, 
genistein; B, dynasore; C, chlorproazine; D, MbCD. 
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Figure 7. Effect of inhibitors on internalization of CDplexes. Vero cells were pretreated with 
the inhibitors for 1 h. Subsequently, fluorescently labeled CDplexes were added and 
incubated with the cells in the presence of inhibitors for 2 h (400 µM genistein, white bars and 
∆; 50 µM dynasore, dotted bars and ○; 10 µg mL-1 chlorpromazine, hatched bars and +; 5 mM 
MbCD, cross-hatched bars and ×.  
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Figure 8. In vitro transfection efficiencies of CDplexes (N/P 10) in Vero cells in the presence 
of the indicated inhibitor. 
 
